[
    [
        {
            "time": "2018-07-01",
            "original_text": "Analyst Recommendations for Valeant Pharmaceuticals in July",
            "features": {
                "keywords": [
                    "Analyst",
                    "Recommendations",
                    "Valeant Pharmaceuticals"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Analyst Recommendations for Valeant Pharmaceuticals in July",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay",
            "features": {
                "keywords": [
                    "J&J",
                    "Invokana",
                    "Label Expansion",
                    "FDA Delay"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay",
            "features": {
                "keywords": [
                    "J&J",
                    "Invokana",
                    "Label Expansion",
                    "FDA Delay"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon",
            "features": {
                "keywords": [
                    "Zacks Analyst Blog",
                    "PepsiCo",
                    "Eli Lilly",
                    "Broadcom",
                    "Biogen",
                    "Marathon"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "consumer goods",
                    "biotech",
                    "semiconductors",
                    "pharmaceuticals",
                    "energy"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]